COSM Cosmos Health Inc.

Cosmos Health Inc.

Other Pharmaceuticals

Health Care

Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.

IPO Year:

Exchange: NASDAQ

Website: https://www.cosmosholdingsinc.com

Recent Analyst Ratings for Cosmos Health Inc.

Date	Price Target	Rating	Analyst

See more ratings

Cosmos Health Inc. Press Releases

Fastest customizable press release news feed in the world

View All

Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions

Continues to deliver record revenue and improving operating metricsSignificant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75%NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibilityEvaluating potential monetization

3/19/26 12:45:00 PM ET

Cosmos Health Inc.

Recent Analyst Ratings for Cosmos Health Inc.

Cosmos Health Inc.

Recent Analyst Ratings for Cosmos Health Inc.

Cosmos Health Inc. Insider Purchases

Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $175,000 worth of shares (353,321 units at $0.50), increasing direct ownership by 5% to 8,091,795 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $220,000 worth of shares (493,495 units at $0.45), increasing direct ownership by 7% to 7,738,474 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $57,000 worth of shares (113,185 units at $0.50), increasing direct ownership by 2% to 7,244,979 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $81,000 worth of shares (156,190 units at $0.52), increasing direct ownership by 2% to 7,131,794 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $65,000 worth of shares (124,880 units at $0.52), increasing direct ownership by 2% to 6,975,604 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $72,000 worth of shares (133,953 units at $0.54), increasing direct ownership by 2% to 6,850,724 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $43,000 worth of shares (88,314 units at $0.49), increasing direct ownership by 1% to 6,716,771 units (SEC Form 4)

Cosmos Health Inc. Insider Trading

Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $175,000 worth of shares (353,321 units at $0.50), increasing direct ownership by 5% to 8,091,795 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $220,000 worth of shares (493,495 units at $0.45), increasing direct ownership by 7% to 7,738,474 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $57,000 worth of shares (113,185 units at $0.50), increasing direct ownership by 2% to 7,244,979 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $81,000 worth of shares (156,190 units at $0.52), increasing direct ownership by 2% to 7,131,794 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $65,000 worth of shares (124,880 units at $0.52), increasing direct ownership by 2% to 6,975,604 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $72,000 worth of shares (133,953 units at $0.54), increasing direct ownership by 2% to 6,850,724 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $43,000 worth of shares (88,314 units at $0.49), increasing direct ownership by 1% to 6,716,771 units (SEC Form 4)

Cosmos Health Inc. SEC Filings

Amendment: SEC Form S-3/A filed by Cosmos Health Inc.

SEC Form 424B3 filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

Cosmos Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Cosmos Health Inc.

SEC Form S-3 filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Cosmos Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

Cosmos Health Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

SEC Form DEFA14A filed by Cosmos Health Inc.

Cosmos Health Inc. Press Releases

Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000

Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value

Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK's Second-Largest Beauty and Health Retailer

Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK's Largest Retailer

Cosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026

Cosmos Health Expands Digital Assets Program with $500,000 Bitcoin Purchase, Bringing Total Cryptocurrency Investments to $2.5 Million; Evaluates Inclusion of Other Select Cryptocurrencies

Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue

Cosmos Health Inc. Leadership Updates

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor

Cosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer

Cosmos Holdings Appoints Dr. Manfred Ziegler to its Advisory Board

Cosmos Holdings Appoints Finance Veteran Dr. Anastasios Aslidis to the Board of Directors and as a Member of the Board's Audit Committee

Cosmos Health Inc. Financials

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Issues Letter to Shareholders

Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform

Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market

Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio

Cosmos Health Reports First Quarter 2023 Financial Results; Delivers Positive Adjusted EBITDA and Significant Increase in Adjusted Net Income

Cosmos Health Advances Its Strategic Plan; Acquires Distressed Property Housing Operations of CosmoFarm, Expected to Generate Substantial Value for Shareholders

Cosmos Health Inc. Enters U.S. Telehealth Space with Successful Acquisition of ZipDoctor, Inc.

Cosmos Health Announces Application for Dual Listing on Upstream

Cosmos Health Inc. Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

SEC Form SC 13D/A filed by Cosmos Holdings Inc. (Amendment)

SEC Form SC 13D filed by Cosmos Holdings Inc.

SEC Form SC 13D/A filed by Cosmos Holdings Inc. (Amendment)

SEC Form SC 13D filed by Cosmos Holdings Inc.